Tuberculosis (TB) is one of the major public health concerns and one of the leading causes of death worldwide. One of the major challenges in the treatment and prevention of tuberculosis is the emergence of multidrug resistant or even extensively drug resistance tuberculosis (MDR/XDR-TB). There is an urgent unmet need for the development of new therapies for the treatment of MDR/XDR-TB.
TNP-2500, a representative compound of a series of multi-targeting molecules, attacks two molecular targets in Mycobacterium tuberculosis. It demonstrated potent activities against MDR/XDR clinical isolates and excellent bactericidal activities against M. tuberculosis under hypoxic conditions. The successful development of the TNP-2500 series is expected to provide a improved therapy for the treatment of MDR/XDR-TB.